Skip to main content
Fig. 3 | World Journal of Surgical Oncology

Fig. 3

From: PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China

Fig. 3

Kaplan–Meier survival curves. a Patients with different ER status in group H. b Patients with different PR status in group H. c Patients with different ER status in group HP. d Patients with different PR status in group HP. e Patients stratified by anti-HER2 treatment in ER + cohort. f Patients stratified by anti-HER2 treatment in ER − cohort. g Patients stratified by anti-HER2 treatment in PR + cohort. h Patients stratified by anti-HER2 treatment in PR − cohort

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us